Pacific biosciences of california stock.

Pacific Biosciences Of California. stock was originally listed at a price of $16.44 in Oct 27, 2010. If you had invested in Pacific Biosciences Of California stock …

Pacific biosciences of california stock. Things To Know About Pacific biosciences of california stock.

24 Jan, 2023, 16:05 ET. MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it intends to offer and sell $150.0 ...Nov 13, 2023 · Pacific Biosciences of California Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Pacific Biosciences of California Inc’s trailing 12-month revenue is $169.5 million with a -182.3% profit margin. Year-over-year quarterly sales growth most recently was 72.4%. Pacific Biosciences. Pacific Biosciences of California, Inc. (aka PacBio) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. [2] [3] [failed verification] PacBio has two principal sequencing platforms: single-molecule real-time ... Pacific Biosciences of California, Inc. (PACB) latest earnings report: revenue, EPS, surprise, history, news and analysis.

Nov 26, 2023 · Pacific Biosciences of California Stock Up 2.3 %. Shares of NASDAQ:PACB opened at $8.55 on Friday. The company has a debt-to-equity ratio of 1.17, a current ratio of 4.80 and a quick ratio of 4.43. Oct. 31. MT. Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $10 From $13, Maintains Equal-Weight Rating. Oct. 24. MT. Barclays Cuts Price Target on Pacific Biosciences of California $9 From $14, Maintains Equalweight Rating. Sep. 29. MT. Bernstein Starts Pacific Biosciences of California With Outperform Rating, $11 ... Nov 2, 2023 · Stock Quote. Price Change Change(%) Volume 52 Week High 52 Week Low ... Pacific Biosciences of California, Inc. 1305 O’Brien Drive, Menlo Park, CA 94025 [email protected].

The Pacific Biosciences of California stock prediction results are shown below and presented as a graph, table and text information. Pacific Biosciences of California stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Pacific Biosciences of California analysts is $. Today ...

Pacific Biosciences of California Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Pacific Biosciences of California Inc’s trailing 12-month revenue is $169.5 million with a -182.3% profit margin. Year-over-year quarterly sales growth most recently was 72.4%.Reassessing Pacific Biosciences: Deep Dive Into Q3 2023 Revenue Surge And Market Dynamics 11/20/23-9:07AM EST Seeking Alpha Pacific Biosciences of California rises after UBS upgrades on strong ...Management will host a quarterly conference call to discuss its first quarter ended March 31, 2022, results today at 5:00 p.m. Eastern Time. Investors may listen to the call by dialing 866-652-5200, or if outside the U.S., by dialing 412-317-6060, and request to join the “PacBio Q1 Earnings Call.”. The call will be webcast live and will be ...Nov 16, 2023 · Get the latest Pacific Biosciences of California Inc. (PACB) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.

Pacific Biosciences of California (NASDAQ:PACB) and Olink Holding AB (publ) are both mid-cap medical companies, but which is the superior business?We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Pacific Biosciences of California, Inc. Common Stock (PACB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Pacific Biosciences of California, Inc. (aka PacBio) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. [failed verification] PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the …STOCK INFORMATION IRS Notification. Form 8937 Omniome. Stock Quote ... Pacific Biosciences of California, Inc. 1305 O’Brien Drive, Menlo Park, CA 94025Pacific Biosciences of California Stock Up 4.7 %. Pacific Biosciences of California stock opened at $8.88 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 4.43 and a ...Two of Cathie Wood's Ark Invest ETFs loaded up on shares of Pacific Biosciences of California (PacBio). PacBio is an innovative disruptor in the genetic sequencing market. However, the company ...Pacific Biosciences of California (NASDAQ:PACB) rose 3.16% Friday pre-market after UBS upgraded the sequencing systems company on a strong "Revio" demand. ... The stock is currently trading at $7. ...

Find the latest Pacific Biosciences of California, Inc. (PACB) stock quote, history, news and other vital information to help you with your stock trading and investing. Home. Mail; News; Sports; Finance; ... Pacific Biosciences of California, Inc. (PACB) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Add to watchlist. 8.55 +0.19 (+2.27%)View the latest Pacific Biosciences of California Inc. (PACB) stock price, news, historical charts, analyst ratings and financial information from WSJ.PacBio Also Closes $300 Million PIPE Financing in Support of Transaction. MENLO PARK, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Omniome, a San Diego-based biotechnology ...Dec 2, 2023 · Pacific Biosciences of California Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 8.02. Negative dynamics for Pacific Biosciences of California shares will prevail with possible volatility of 5.469%. Pessimistic target level: 7.80. Apr 30, 2021 · PacBio announced record first-quarter revenue of $29 million, an 86% year-over-year increase and exactly what analysts expected. Meanwhile, the company recorded a net loss of $87.4 million -- or a ... Pacific Biosciences of California, Inc. Q4 Loss Increases, but beats estimates. (RTTNews) - Pacific Biosciences of California, Inc. (PACB) released Loss for its fourth quarter that increased from ...

MENLO PARK, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced the appointment of Susan G. Kim as Chief Financial Officer, effective as of September 28, …

24 Jan, 2023, 23:18 ET. MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it has priced its previously ...As of Tuesday, October 31, Pacific Biosciences of California Inc’s PACB share price has dipped by 13.08%, which has investors questioning if this is right time to buy. Premium Products ... Stock Superstars Report Get stock ideas inspired by the market's leading professionals; VMQ Stocks For the ...PacBio announced record first-quarter revenue of $29 million, an 86% year-over-year increase and exactly what analysts expected. Meanwhile, the company recorded a net loss of $87.4 million -- or a ...Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock ...Dec 2, 2023 · Pacific Biosciences of California Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 8.02. Negative dynamics for Pacific Biosciences of California shares will prevail with possible volatility of 5.469%. Pessimistic target level: 7.80. KGI Securities started coverage on Pacific Biosciences of California and gave it an “outperform” rating in their report released on Wednesday June 7th. Morgan Stanley increased its price target for Pacific Biosciences of California from $12.00 to $13.00 and gave the stock an “equal weight” rating in their report on Thursday, August 3rd.Nov 19, 2023 · Pacific Biosciences of California Inc. (PACB) Stock Performance and Future Outlook in the Health Technology Sector. On November 19, 2023, Pacific Biosciences of California Inc. (PACB) had an eventful day in the stock market. PACB started the day with an opening price of $7.82, slightly higher than its previous closing price of $7.59. Pacific Biosciences of California (PACB): Stock Market Performance, Earnings Growth, and Market Analysis. On June 30, 2023, Pacific Biosciences of California (PACB) had a mixed performance in the stock market. The stock opened at $13.77 and fluctuated between $13.59 and $14.07 throughout the day. The trading …

As of November 1, 2023, Canaccord Genuity analyst Kyle Mikson has reaffirmed a Buy rating on Pacific Biosciences (NASDAQ:PACB), although ... Best stocks to buy now; Categories. Crypto; Dow Jones today; Pre-IPO and startups; Tech stocks; Utility stocks; Best Stocks tools HOT. Stock News Sentiment;

٢٥‏/٠٩‏/٢٠٢٣ ... Why Pacific Biosciences of California Inc's (PACB) Stock Is Down 5.37% ... Avoid the stress of overpaying for a stock or missing an opportunity by ...

Pacific Biosciences of California Inc’s price is currently up 8.37% so far this month. During the month of March, Pacific Biosciences of California Inc’s stock price has reached a high of $10.00 and a low of $8.52. Over the last year, Pacific Biosciences of California Inc has hit prices as high as $14.20 and as low as $3.85.Track Pacific Biosciences of California Inc (PACB) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2021.Track Pacific Biosciences of California Inc (PACB) Stock Price, Quote, latest community messages, chart, news and other stock related information.Pacific Biosciences' Q3 2023 highlighted the adoption of their Revio system, particularly among new customers. Read why PACB stock is a Buy.Natural resources in California include waterways such as the San Joaquin Delta, the Pacific Ocean coastline, natural parks, plants and wildlife, and numerous habitats and ecosystems. Natural resources in California provide many economic an...Pacific Biosciences of California Inc. PACB (U.S.: Nasdaq) Pacific Biosciences of California Inc. View All companies. REAL TIME 12:47 PM EST 11/30/23. $8.62 USD.٢٥‏/٠٩‏/٢٠٢٣ ... Why Pacific Biosciences of California Inc's (PACB) Stock Is Down 5.37% ... Avoid the stress of overpaying for a stock or missing an opportunity by ...Nov 24, 2023 · 11 analysts have issued 1 year price objectives for Pacific Biosciences of California's stock. Their PACB share price targets range from $8.00 to $17.00. On average, they predict the company's stock price to reach $11.80 in the next year. This suggests a possible upside of 38.0% from the stock's current price. Stocks of Pacific Biosciences of California Inc saw a sharp rise in short interest on Nov 14, 2023 jumping by 1.49 million shares to 39.23 million. Data from Yahoo Finance shows that the short interest on Oct 12, 2023 was 37.74 million shares. A jump of 3.8% in short interest reflects a negative sentiment towards the stock.Reassessing Pacific Biosciences: Deep Dive Into Q3 2023 Revenue Surge And Market Dynamics 11/20/23-9:07AM EST Seeking Alpha Pacific Biosciences of California rises after UBS upgrades on strong ...

Get the latest PACB stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's earnings, …Pacific Biosciences of California Revenue Forecast for 2023 - 2025 - 2030. Pacific Biosciences of California's Revenue has grown In the last three years, rising from $90.89M to $128.30M – a growth of 41.16%. In the next year, analysts believe that Revenue will reach $196.94M – an increase of 53.50%. For the next nine years, experts predict ...And the warming slowdown. To understand why the west has been so dry since the turn of the century, cast your eye further west—to the natural waxing and waning of Pacific Ocean winds. Strong trade winds have been forcing heat into ocean dep...As of February 15, 2023, 4:00 PM CST, Pacific Biosciences of California Inc’s stock price was $11.09. Pacific Biosciences of California Inc is up 7.88% from its previous closing price of $10.28. During the last market session, Pacific Biosciences of California Inc’s stock traded between $9.75 and $10.47.Instagram:https://instagram. best international brokerscop earningstootsie roll industries incchecking account with virtual debit card Pacific Biosciences of California Inc’s price is currently up 5.51% so far this month. During the month of March, Pacific Biosciences of California Inc’s stock price has reached a high of $10.00 and a low of $8.01. Over the last year, Pacific Biosciences of California Inc has hit prices as high as $14.20 and as low as $3.85. w.p. carey stock forecastnugt shares Pacific Biosciences of California is forecast to grow earnings and revenue by 30.8% and 30.6% per annum respectively. EPS is expected to grow by 33.7% per annum. Return on equity is forecast to be -58.8% in 3 years.Find the latest Pacific Biosciences of California, Inc. (PACB) stock quote, history, news and other vital information to help you with your stock trading and investing. snpa stock Nov 28, 2023 · In other Pacific Biosciences of California news, insider Christian O. Henry sold 96,844 shares of the stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $10.12, for a total value of $980,061.28. Pacific Biosciences of California Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Pacific Biosciences of California Inc’s trailing 12-month revenue is $169.5 million with a -182.3% profit margin. Year-over-year quarterly sales growth most recently was 72.4%.